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H I G H L I G H T S
• PAD patients have a high risk of all-cause and cardiovascular (CV) mortality.• Patients with critical limb ischaemia were at highest risk (versus ABI< 0.9).• Fewer patients with critical limb ischaemia received statins (versus ABI<0.9).• The risk of stroke or MI is at least equivalent to that of coronary artery disease.• Improved treatments are needed to attenuate CV risk in PAD patients.
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A B S T R A C T
Background and aims: It is unclear whether improvements in the detection/treatment of peripheral artery disease
(PAD) affect overall survival and morbidity. We undertook a systematic review to describe survival and mor-
bidity in contemporary PAD cohorts.
Methods: Electronic databases were searched for randomised and observational studies reporting mortality/
morbidity events between 1 May 2003 and 31 December, 2017 in patients with PAD, diagnosed by intermittent
claudication (IC), critical limb ischaemia (CLI), or an ankle brachial index (ABI) < 0.9. Pooled event rates for
all-cause and cardiovascular (CV) mortality, non-fatal myocardial infarction (MI), non-fatal stroke, major CV
events (MACE; non-fatal MI/stroke, CV death), and major amputation were calculated per 1000 person-years.
Results: 124 eligible studies were identified (570,856 patients; 855,894 person-years of follow-up). Statin use
was reported in 67% of the overall cohort and antiplatelet use in 79%. Pooled event rates for all-cause and CV
mortality, MI, stroke, MACE, and major amputation were 113, 39, 20, 12, 71, and 70 per 1000 person-years,
respectively. Compared with patients with an ABI<0.9, the presence of CLI was associated with increased rates
of all-cause and CV mortality, MI, MACE, and major amputation. Event rates for stroke were similar between
patients with an ABI< 0.9 and CLI.
Conclusions: Our data show PAD patients have a high risk of all-cause and CV mortality, and imply the risk of
stroke or MI is at least equivalent to the risk in patients with coronary artery disease. Moreover, our data
underline the need for improved treatments to attenuate CV risk in PAD patients.
1. Introduction
Atherosclerotic peripheral artery disease (PAD) remains an under-
diagnosed and undertreated disease [1,2]. It is estimated that more
than 200 million people worldwide are affected [3], which is associated
with premature cardiovascular (CV) events and death. The morbidity
and mortality associated with PAD are known to be equal to or higher
than those associated with coronary heart disease (CHD) [4,5]. This is
not surprising, given the common risk factors for atherosclerotic CV
disease (CVD) and that patients with PAD often have concomitant
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coronary and cerebrovascular disease [6].
A previous systematic literature review (SLR) from the Ankle
Brachial Index (ABI) Collaboration, examining the association between
an ABI< 0.9 with mortality and CVD in studies published between
1980 and 2005 [7], reported a 60% excess risk of all-cause mortality
and a 96% increase in CV deaths. An update of this SLR is timely be-
cause it remains unclear to what extent improvements in PAD diag-
nosis, the rising number of revascularisation procedures performed, and
advances in CV risk modification have an effect on overall survival and
morbidity in patients with PAD [8,9]. Furthermore, the clinical spec-
trum of PAD is wide and includes individuals with symptoms of inter-
mittent claudication (IC) and critical limb ischaemia (CLI), in addition
to those diagnosed using the ABI measure of perfusion, who may be
asymptomatic. In addition, symptomatic patients with PAD appear to
be at higher overall risk of mortality than asymptomatic patients
[10,11].
Our objective was to systemically review the current evidence re-
garding rates of all-cause and CV mortality, myocardial infarction (MI),
stroke, major adverse cardiovascular events (MACE; non-fatal MI, non-
fatal stroke, CV death), and major amputation in PAD.
2. Materials and methods
2.1. Search strategy
This systematic review was conducted according to the protocol
registered with PROSPERO (Registration number CRD42017077983)
and in accordance with PRISMA and MOOSE guidelines [12,13]. The
online databases MEDLINE, Embase, Cumulated Index to Nursing and
Allied Health Literature (CINAHL), and Cochrane Central Register of
Controlled Trials (CENTRAL) were searched for medical subject
heading (MeSH) and keywords related to PAD, IC, CLI, mortality, MI,
stroke, and major amputation (Supplementary Data 1).
These searches were supplemented by examining reference lists of
included studies, reviews, and meta-analyses [14,15]. No language re-
strictions were applied.
Inclusion criteria were as follows: (1) randomised controlled trial
(RCTs) and observational studies; (2) reporting mortality or morbidity
events recorded between 1 May, 2003 and 31 December, 2017 among
patients with PAD, defined as the presence of IC, CLI, or an ABI< 0.9;
(3) with ≥200 study participants with PAD; (4) reporting exclusively
on individuals aged ≥40. Studies with cohorts including patients with
CVD in other vascular beds (e.g., coronary artery disease) were in-
cluded only if outcomes in patients with PAD were reported separately
or if≥ 80% of the overall cohort had PAD.
2.2. Data extraction and quality assessment
Two reviewers independently screened all titles and abstracts to
identify articles suitable for full-text review. These reviewers then in-
dependently screened full-text articles, with differences resolved by
consensus, and extracted the following data from eligible studies
(where available): study details (study name, design, country/coun-
tries, number of PAD patients, method of PAD diagnosis, intervention,
study period); patient characteristics (age, gender, prevalent obesity,
hyperlipidaemia, hypertension, diabetes, smoking history); medication
use (statin, other lipid-lowering therapy, antiplatelet, anticoagulation,
β-blocker, angiotensin-convertase-inhibitor [ACEi]/angiotensin re-
ceptor blockade [ARB]); and outcomes (all-cause mortality, CV mor-
tality, stroke, MI, MACE, and major amputation). For each outcome, the
total number of events and mean follow-up duration were extracted, to
allow for the calculation of event rates per 1000 person-years.
Following data extraction, two reviewers independently assessed
the quality of studies using two separate tools. RCTs were assessed
using the Cochrane Risk of Bias Tool. This tool assesses bias as a jud-
gement (high, low, or unclear) for individual study elements from five
domains (selection, performance, attrition, reporting, and other) [16].
Observational studies were assessed using the Risk of Bias for Non-
Randomised Studies-Interventions (ROBINS-I) tool [17]. This tool as-
sesses bias across seven domains: (1) bias due to confounding, (2) bias
in selection of participants, (3) bias in classification of interventions, (4)
bias due to deviations from intended interventions, (5) bias due to
missing data, (6) bias in measurement of outcomes and (7) bias in se-
lection of the reported result, and defines overall risk of bias as low,
moderate, serious, or critical. Sensitivity analyses excluding studies
with unknown, serious, or critical risk of bias for the primary and
secondary outcomes were planned.
2.3. Statistical analyses
Where available, summary characteristics of included patients were
presented as mean values weighted by study size. The primary out-
comes were event rates for all-cause and CV mortality reported per
1000 person-years. Secondary outcomes were event rates for MI, stroke,
MACE, and major amputation. Where not directly reported, event rates
were calculated by dividing the absolute number of events by the total
person-years of follow-up. Pooled event rates were weighted by study
size (number of participants with PAD).
Associations between method of PAD diagnosis and outcomes (pri-
mary and secondary) were assessed using random-effects analyses
(heterogeneity was high, as measured by the I2 statistic) [18]. Specifi-
cally, cohorts including (1) patients with an ABI< 0.9, IC, or CLI
(mixed cohort) and (2) patients with a PAD diagnosis based only on CLI
(CLI cohort) were compared to patients with a PAD diagnosis based
only on an ABI< 0.9 (ABI< 0.9 cohort). These analyses were per-
formed using SPSS Statistics version 25 (IBM) and STATA statistical
software version 12 (StataCorp).
3. Results
3.1. Study characteristics
Of 11,520 potentially relevant publications, 807 were identified for
full-text review and 124 were included in the final analysis (Fig. 1). The
Fig. 1. Study selection.
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main reasons for excluding studies were: they did not report any of the
primary or secondary outcomes or did not permit calculation of event
rates (n=236 [35%]), outcomes were recorded outside the study
period (n=180 [26%]), or they reported duplicate data (n=157
[23%]). The majority of included studies were based on cohort studies
or registry data (n= 78 [63%] and 27 [22%], respectively); 15%
(n=19) were RCTs (Supplementary Data 2). Included studies reported
on event rates in 570,856 patients with 855,894 person-years of follow-
up; 107 studies reported all-cause mortality, 23 reported CV mortality,
17 reported stroke events, 21 reported MI events, and 81 reported
major amputation events (Supplementary Data 3).
Characteristics of included patients are summarised by method of
PAD diagnosis in Table 1. Patient characteristics in individual studies
are presented in Supplementary Data 4. Compared with patients with
an ABI< 0.9, those with CLI were more likely to be male and diabetic,
and less likely to smoke. While prevalence of hyperlipidaemia was si-
milar for patients with ABI< 0.9 and those with CLI (48% and 42%,
respectively), statin use was higher in patients with an ABI< 0.9 (76%
versus 55%, respectively). In the overall PAD cohort, 67% of patients
were receiving statins, 55% receiving ACEi/ARB, and 79% receiving
antiplatelet medication.
3.2. Main outcomes
Event rates are summarised by method of diagnosis in Table 2. In
the overall cohort, event rates for all-cause and CV mortality were 113
and 39 per 1000 person-years, respectively. Compared with patients
with an ABI< 0.9, the presence of CLI was associated with an increased
event rate for all outcomes studied except stroke (Table 2, Fig. 2). The
risk of all-cause mortality was more than two-fold higher among pa-
tients with CLI (183 vs 81 events/1000 person-years; Relative risk [RR],
2.26, 95% confidence interval [CI], 1.77–2.89). The risk of MI was also
more than two-fold higher among patients with CLI (42 vs 16 events/
1000 person-years; RR, 2.63, 95% CI, 1.49–4.64), and the risk of major
amputation almost four-fold higher (100 vs 26 events/1000 person-
years; RR, 3.85, 95% CI, 2.52–5.87). The risk of CV mortality and MACE
were approximately one and a half-fold higher (74 vs 52 events/1000
person-years; RR, 1.42, 95% CI, 1.01–2.01 and 95 vs 55 events/1000
person-years; RR, 1.73, 95% CI, 1.25–2.38).
In exploratory analyses, we compared event rates from studies that
commenced before 2008 with those from studies that commenced after
2008. In the overall cohort, event rates for all-cause mortality were
similar between the two groups, 111 vs 108 per 1000 person-years.
Event rates for CV mortality were higher in studies that started before
2008 than in those that started after 2008, 46 vs 36 per 1000 person-
years, respectively (Supplementary Data 4a). When comparing event
rates from studies with longer or shorter observation periods (in com-
parison to the mean observation period of 1.3 years), event rates for all-
cause mortality were higher in studies with a shorter observation period
compared with those in studies with a longer observation period (123
versus 82 per 1000 person-years, respectively) (Supplementary Data
4b). We also compared event rates from studies with a median year of
observation during the first half of our inclusion period (i.e.
2003–2010) with event rates from studies with a median year of ob-
servation during the second half of our inclusion period (i.e.
2011–2017) (Supplementary Data 5.1–5.4). We observed no apparent
change in the rates of major amputations; the pooled event rate (70 per
1000 person-years) was the same for studies with a median study year
in the first and second halves of our inclusion period. We observed a
trend towards decreasing event rates for all-cause mortality (119 vs 108
per 1000 person-years), CV mortality (46 vs 36 per 1000 person-years),
and MACE (83 vs 67 per 1000 person-years) in the second half of our
Table 1
Patient characteristics by method of PAD diagnosis.
ABI < 0.9 (n= 2708) CLI (n= 370,754) Mixed (n= 197,394) Overall (n=570,856)
Age, years, mean (SD) 68 (11) 69 (13) 69 (10) 69 (13)
Men, % 50 58 63 60
BMI, kg/m2 (SD) 28 (5) 25 (6) 28 (5) 27 (5)
Hyperlipidaemia, % 48 42 52 44
Hypertension, % 75 77 77 77
Diabetes, % 42 55 40 50
Smoking history, % 74 44 71 47
Current smoker, % 50 12 27 27
Statin, % 76 55 68 67
Antiplatelet, % 80 82 79 79
Beta blocker, % 48 44 54 53
ACEi/ARB, % 65 52 56 55
Anticoagulation, % 19 17 10 13
CKDa, % 36b 26 18 22
ABI, ankle brachial index; ACEi, angiotensin convertase enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CKD, chronic kidney disease;
CLI, critical limb ischaemia; SD, standard deviation. Summary statistics are weighted by study size.
a Additional data on renal disease are available in Supplementary Data 3.
Table 2
Pooled event rates per 1000 person-years by method of PAD diagnosis.
Event rates (range) per 1000 person-yearsa ABI < 0.9 (n= 2708) CLI (n= 370,754) Mixed (n= 197,394) Overall (n=570,856)
All-cause mortality 81 (39–173) 183 (25–468) 86 (14–185) 113 (14–468)
CV mortality 52 74 (16–126) 35 (10–75) 39 (10–126)
Stroke 11 9 12 (7–50) 12 (7–50)
MI 16 42 (8–51) 19 (4–65) 20 (4–65)
MACE 55 95 (27–170) 70 (36-230 71 (27–230)
Major amputation 26 (2–103) 100 (10–232) 37 (2–140) 70 (2–232)
ABI, ankle brachial index; CLI, critical limb ischaemia; CV, cardiovascular; MACE, major adverse cardiovascular events. MI, myocardial infarction. Event rates are
weighted by study size. Where no range is presented, data derive from a single study.
a Of the included studies, 107 reported all-cause mortality, 23 reported CV mortality, 17 reported stroke events, 21 reported MI events, and 81 reported major
amputation event.
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inclusion period. There were insufficient numbers of studies reporting
on event rates for stroke and MI to permit meaningful comparisons over
time.
Among studies reporting exclusively on patients with CLI, we ob-
served a large variation in event rates for all outcomes, including all-
cause mortality, which ranged from 25 to 468 events per 1000 person-
years (Table 2). To assess whether this variation was related to study
design, patient characteristics and event rates for studies reporting only
on patients with CLI were summarised by study design (Table 3). Pa-
tients enrolled in RCTs were of a similar age to those enrolled in ob-
servational studies. Pooled event rates for all-cause mortality, CV
mortality, MI, and MACE were lower in RCTs (88 vs 184, 16 vs 80, 11 vs
47, and 27 vs 123 per 1000 person-years, respectively). Conversely, the
pooled event rate for major amputation was higher in RCTs (142 vs 99
per 1000 person-years), which may relate to a higher prevalence of
diabetes which was observed in the RCTs.
3.3. Risk of bias
The overall risk of bias for RCTs, measured using the Cochrane Risk
of Bias Tool, was low in 17 studies and unclear in 2 studies
(Supplementary Data 6). In sensitivity analyses excluding RCTs judged
to be of unclear bias, event rates were similar to those observed in the
main analyses. The overall risk of bias in observational studies, as as-
sessed using the Robins-I tool, was moderate for all studies
(Supplementary Data 7). Our analyses did not assess the effect of any
intervention(s) on outcome measures, therefore no study was con-
sidered to have deviated from an intended intervention.
4. Discussion
Our systematic review of both RCTs and observational studies shows
that PAD carries at least a comparable risk of all-cause and CV mortality
events to disease in other vascular beds, as reported in other observa-
tional studies. The overall rate of all-cause mortality we observed (113/
1000 person-years) exceeds that reported in patients with coronary
artery disease in the Cardiovascular Health Study (71/1000 person-
years) [19], the Reduction of Atherothrombosis for Continued Health
(REACH) registry (26/1000 person-years) [20], and the Renfrew and
Paisley cohort (47–51/1000 person-years) [21]. Furthermore, the
overall rate of CV mortality we observed (39/1000 person-years) is
comparable with the Antithrombotic Trialists’ Collaboration meta-
Fig. 2. Association of critical limb ischaemia with outcomes (using patients with ABI<0.9 as the reference group).
Patients with ABI<0.9 used as the reference category; ABI ankle brachial index; CLI, critical limb ischaemia; RR, relative risk.
Table 3
Critical limb ischaemia patient characteristics and pooled event rates per 1000
person-years by study design.
RCT (n= 1602) Observational (n=369,152)
Patient characteristics
Age, years, mean (SD) 69 (8) 69 (13)
Men, % 70 58
BMI, kg/m2 (SD) 28 (5) 24 (5)
Hyperlipidaemia, % 66 42
Hypertension, % 82 77
Diabetes, % 70 56
Smoking history, % 39 44
Current smoker, % NA 12
Statin, % 58 55
Antiplatelet, % 75 82
Beta blocker, % 46 44
ACEi/ARB, % 60 51
Anticoagulation, % 32 15
Event rates (range) per 1000 person-years
All-cause mortality 88 184
CV mortality 16 80
Stroke 9 NA
MI 11 47
MACE 27 123
Major amputation 142 99
ACEi, angiotensin convertase enzyme inhibitor; ARB, angiotensin receptor
blocker; BMI, body mass index; CV, cardiovascular; MACE, major adverse
cardiovascular events; MI, myocardial infarction; NA, not available; RCT, ran-
domised controlled trial; SD, standard deviation.
Summary statistics are weighted by study size. Where no range is presented,
data derive from a single study.
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analysis of RCTs enrolling participants with previous MI or stroke (40/
1000 person-years) [22].
Our findings extend those of a previous systematic review in-
vestigating the association of low ABI with mortality and CVD [7], by
reporting event rates stratified by method of PAD diagnosis. In the
previous review, which included 11 studies reporting on 44,590 parti-
cipants, an ABI< 0.9 was associated with an increased risk of all-cause
and CV mortality compared with an ABI ≥0.9 (RR, 1.60, 95% CI,
1.32–1.95 and 1.96, 1.46–2.64, respectively). In our study, compared
with an ABI< 0.9, the presence of CLI was associated with an increased
risk of all-cause and CV mortality (RR, 2.26, 95% CI, 1.77–2.89 and
1.42, 1.01–2.01, respectively), MI (RR, 2.63, 95% CI, 1.49–4.64), MACE
(RR, 1.73, 95% CI, 1.25–2.38) and major amputations (RR, 3.85, 95%
CI, 2.52–5.87). The event rates for stroke were similar in patients with
an ABI< 0.9 or CLI.
The overall event rates in our study also imply that the risk of stroke
and MI in a PAD population is at least equivalent to the risk of these
events in patients with coronary artery disease (CAD). In the REACH
registry [20], event rates for stroke and MI among patients with CAD
were 12 and 13 per 1000 person-years, respectively, compared with 12
and 20 per 1000 person-years, respectively, in our study. In the COM-
PASS study of patients with stable atherosclerotic CVD randomised to
rivaroxaban, rivaroxaban + aspirin, or aspirin alone, event rates for the
primary outcome of CV death, stroke or MI were higher in the PAD
subgroup as compared with the CAD subgroup [23]. The CV event rates
reported in our PAD cohort have important implications for preventive
therapy, which previous studies have reported to be inadequate
[24–26]. The 2011 Practice Guidelines from the American College of
Cardiology Foundation (ACCF) and the American Heart Association
(AHA) support the use of an antiplatelet to reduce the risk of CV events
among patients with IC, CLI, prior revascularisation or amputation for
lower limb ischaemia (Class 1A recommendation) [27].
In our cohort, antiplatelet therapy was reported in 82% of patients
with CLI, comparable with that reported among patients with CAD in
REACH (86%) [20]. It is less well established whether antiplatelet
therapy is indicated in asymptomatic individuals with an ABI ≤0.9
(Class 2C recommendation). The Aspirin for Asymptomatic Athero-
sclerosis (AAA) trial enrolled 3350 individuals free of clinical CVD with
a low ABI (≤0.95) and found no significant reduction in vascular
events among patients treated with aspirin 100mg compared with
placebo [28]. Consistent with results from the AAA trial, the Prevention
of Progression of Arterial Disease and Diabetes (POPADAD) trial found
no evidence to support the use of aspirin for primary prevention among
patients with diabetes and an ABI< 0.99 [29]. Two meta-analyses
examining the role of antiplatelet agents among asymptomatic patients
with PAD provide conflicting results; Berger et al. reported no benefit of
antiplatelets in reducing all-cause and CV mortality [28], whereas the
Antiplatelet Trialists’ Collaboration analyses support the use of anti-
platelet agents (including dipyridamole and ticlopidine) in all patients
with atherosclerotic vascular disease [30]. Our findings suggest that
antiplatelet therapy among individuals with an ABI< 0.9 may be in-
creasing, with the proportion of patients receiving any antiplatelet
therapy in our cohort (2003–2017, 80%) greater than that reported in
the National Health and Nutrition Examination Study (1999–2004,
49%).
Analyses of the REACH registry found treatment with ≥2 pre-
ventive therapies (including aspirin, statin and/or ACEi/ARB) to be
associated with a 65% reduced risk of all-cause mortality among in-
dividuals with PAD, as identified by an ABI ≤0.9, but with no prior
history of CVD [26]. In our PAD cohort, 79%, 67% and 55% of patients
were receiving an antiplatelet, statin and ACEi/ARB, respectively,
suggesting there may be opportunity to further reduce CV events
through more effective use of preventive treatments. Also of note, fewer
patients with CLI in our analyses received statin therapy compared with
those with an ABI< 0.9. Given that event rates for CV death, MI and
MACE were highest in patients with CLI, this is a potential cause for
concern and suggests these patients should be prioritised for CV risk
modification.
Until recently, there was insufficient evidence to confirm the role of
low-density lipoprotein cholesterol (LDL-C) in the pathogenesis of PAD;
indeed several studies showed no significant association between LDL-C
levels and incident PAD [3,31]. More recently, in the Scottish Heart
Health Extended Cohort (SHHEC) of 15,000 individuals observed for 20
years, LDL-C was identified as an independent risk factor for PAD [32].
Irrespective of its role in the pathogenesis of PAD, a wealth of evidence
from observational and randomised studies supports the benefits of
LDL-C lowering in a PAD population. In analyses of a REACH subgroup
with IC and an ABI< 0.9, statin use was associated with a significant
reduction in MACE (HR 0.85, 95% CI, 0.75–0.96) as compared with no
statin therapy [33]. Moreover, in patients with PAD, statin therapy was
shown to reduce the risk of major adverse limb events (including de-
terioration of symptoms, peripheral revascularisation, and amputation)
by 18% [33]. These findings are supported by RCT evidence from the
Heart Protection Study; in a pre-specified subgroup analysis, treatment
with simvastatin reduced the risk of a first major vascular event by 22%
among patients with symptomatic PAD, compared with placebo [34].
Further beneficial effects of statin therapy have been observed in po-
pulations with atherosclerotic CVD including reducing the development
or progression of claudication [35], and preventing restenosis following
endovascular or open bypass revascularisation [36,37].
Both the intensity of lipid-lowering therapy and LDL-C levels
achieved in patients with PAD appear to be determinants of outcome.
The randomised Further Cardiovascular Outcomes Research with
PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial in-
cluded a subgroup of 3642 patients with PAD. In this subgroup, when
added to optimised statin therapy, evolocumab significantly reduced
the risk of MACE (defined as death, MI, stroke, hospitalisation, or
coronary revascularisation) or major adverse limb events (MALE, de-
fined as acute limb ischaemia, major amputation, or urgent peripheral
revascularisation) (HR 0.79, 95% CI, 0.66–0.94) [38]. In addition,
evolocumab significantly reduced LDL-C levels by 59% compared with
placebo, with these reductions maintained over time and a linear re-
lationship observed between lower LDL-C and lower risk of MALE that
extended to LDL-C levels below 10mg/dL. Among patients treated with
placebo, those with PAD had a significantly increased risk of death, MI,
stroke, hospitalisation, or coronary revascularisation compared with
patients without PAD (HR 1.57, 95% CI, 1.36–1.80). In observational
studies involving patients with PAD, increasing the intensity of statin
therapy has been shown to result in lower rates of all-cause and car-
diovascular mortality [39], in addition to reducing rates of lower limb
amputation [40].
The event rates for all-cause mortality, CV mortality and MACE
observed in our PAD cohort were lower in RCTs than in observational
studies. This finding may relate to more optimal management of CV risk
in a RCT setting. Conversely, the event rates for major amputation were
highest in RCTs. However, patients enrolled in RCTs had a higher
prevalence of diabetes, which may explain this finding. Specifically, the
broad overlap of CLI and diabetic foot may confound the appropriate
classification of PAD [41], with patients with the far higher risk of limb
loss associated with diabetic foot, and patients with atherosclerotic CLI
being grouped together.
Of note, the event rates for CV mortality observed in our overall
cohort were higher in studies that commenced before 2008 compared
with the event rates in the studies that commenced after 2008. This
suggests that the publication of the 2005 and 2007 guideline re-
commendations on the management of patients with PAD [42,43] may
have helped to improve CV outcomes. Further research to investigate a
possible causal relationship between changes in guideline re-
commendations and improved outcomes in patients with PAD would be
of interest.
As with any systematic review, our limitations in part reflect those
of the included studies. Data on the outcomes of interest were
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inconsistently reported and, in many studies, outcomes were reported
in mixed cohorts of patients with IC, CLI, or an ABI< 0.9. Of note, no
study reported on IC alone. As such, we were only able to categorise a
small number of patients by the method of PAD diagnosis for compar-
ison of event rates. Furthermore, the data set only included patients
with an ABI< 0.9, which limited the assessment of risk in individual
ABI cohorts; for example, for patients with an ABI> 0.9–1.3 or> 1.3.
In addition, the lack of individual patient data precluded analyses ad-
justed for baseline characteristics, which may have influenced event
rates; thus our findings may be subject to residual confounding. Also,
the inclusion of observational studies in our analyses may have in-
troduced selection biases.
With data on over half a million patients from 124 studies, our study
provides substantially more information on event rates in PAD than
previous systematic reviews. Event rates varied widely between studies,
reflecting the heterogeneous nature of PAD and the broad spectrum of
disease enrolled in the included studies. The variability in event rates
may also be partly a result of global variation in prevalence, phenotype
and outcomes of patients with PAD. In future studies, it would be of
interest to examine the effect of geographical and socio-economic fac-
tors on event rates in these patients. Event rates for all-cause and CV
mortality in our cohort were comparable to those observed in con-
temporary cohorts with CAD, highlighting the need for effective treat-
ments to attenuate the risk of CV events. Patients with CLI were at the
highest overall risk for all outcomes measured with the exception of
stroke, yet fewer patients in this group received statin therapy than
patients with an ABI< 0.9. This observation suggests an opportunity to
prevent more CV and limb events with lipid lowering therapy.
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